Can hepatitis B carriers transmit the virus to others?
Feb 09, 2022
Source: Cainiu Health
Dr. Xing Jian
Introduction
Hepatitis B carriers harbor the virus in their bodies and are therefore infectious to some degree. In some patients, the hepatitis B virus remains in a low-activity state, resulting in relatively low transmissibility; in others, the virus replicates actively, making transmission to others more likely. Thus, hepatitis B carriers should undergo regular medical check-ups to monitor the activity level of the hepatitis B virus.
Hepatitis B generally refers to chronic viral hepatitis B. Chronic viral hepatitis B is defined as a condition in which hepatitis B virus (HBV) testing remains positive for more than six months, or when the onset date is unclear but clinical manifestations consistent with chronic hepatitis are present. So, can HBV carriers transmit the virus to others? Below, we address this question.
Can HBV carriers transmit the virus to others?
Since HBV carriers harbor the virus within their bodies, they possess a certain degree of infectivity. In some individuals, the virus remains in a low-activity state, resulting in relatively low transmissibility. Conversely, in others, active viral replication occurs, significantly increasing the risk of transmission to others. Therefore, HBV carriers should undergo regular medical examinations to monitor the activity level of the virus.
During routine hospital testing, if an HBV carrier is found to be in the active viral replication phase—indicated by a positive hepatitis B e antigen (HBeAg) test—prompt antiviral therapy is essential. Without timely suppression of viral activity, extensive hepatocyte invasion by the virus may progressively lead to liver fibrosis, cirrhosis, and even hepatocellular carcinoma, thereby endangering the patient’s life. Moreover, during this highly replicative phase, the virus exhibits markedly increased infectivity, posing a transmission risk to family members, colleagues, and others in close contact.
To prevent further disease progression, patients should consult experienced hepatologists for appropriate antiviral treatment. Nucleos(t)ide analogues are commonly used for HBV treatment. While many such drugs carry substantial risks of hepatic and renal toxicity, newer agents—such as Vemlidy® (tenofovir alafenamide fumarate tablets)—exhibit minimal renal impact and are suitable for most patients. Vemlidy® selectively targets hepatocytes, effectively suppressing HBV replication and reducing viral load both in serum and liver tissue. Consequently, it lowers viral infectivity and decreases the incidence of cirrhosis and hepatocellular carcinoma.
The above provides an overview of whether HBV carriers can transmit the virus. We hope this information is helpful to you.
